Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Its Association With Comprehensive Genomic Profiling and/or Cell-Free DNA Results

BACKGROUND: Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1–3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothel...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Pal, Sumanta K., Bajorin, Dean, Dizman, Nazli, Hoffman-Censits, Jean, Quinn, David I., Petrylak, Daniel P., Galsky, Matthew D., Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard A., Soifer, Harris S., Li, Gary, Wang, Hao, Dambkowski, Carl L., Moran, Susan, Daneshmand, Siamak, Rosenberg, Jonathan E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515773/
https://ncbi.nlm.nih.gov/pubmed/32208524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32806
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky